FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2092142218> ?p ?o ?g. }

• W2092142218 endingPage "e1000362" @default.
• W2092142218 startingPage "e1000362" @default.
• W2092142218 abstract "Background Neuraminidase inhibitors are thought to be efficacious in reducing the time to alleviation of symptoms in outpatients with seasonal influenza. The objective of this study was to compare the short-term virological efficacy of oseltamivir-zanamivir combination versus each monotherapy plus placebo. Methods and Findings We conducted a randomized placebo-controlled trial with 145 general practitioners throughout France during the 2008–2009 seasonal influenza epidemic. Patients, general practitioners, and outcome assessors were all blinded to treatment assignment. Adult outpatients presenting influenza-like illness for less than 36 hours and a positive influenza A rapid test diagnosis were randomized to oseltamivir 75 mg orally twice daily plus zanamivir 10 mg by inhalation twice daily (OZ), oseltamivir plus inhaled placebo (O), or zanamivir plus oral placebo (Z). Treatment efficacy was assessed virologically according to the proportion of patients with nasal influenza reverse transcription (RT)-PCR below 200 copies genome equivalent (cgeq)/µl at day 2 (primary outcome), and clinically to the time to alleviation of symptoms until day 14. Overall 541 patients (of the 900 planned) were included (OZ, n = 192; O, n = 176; Z, n = 173), 49% male, mean age 39 years. In the intention-to-treat analysis conducted in the 447 patients with RT-PCR-confirmed influenza A, 46%, 59%, and 34% in OZ (n = 157), O (n = 141), and Z (n = 149) arms had RT-PCR<200 cgeq/µl (−13.0%, 95% confidence interval [CI] −23.1 to −2.9, p = 0.025; +12.3%, 95% CI 2.39–22.2, p = 0.028 for OZ/O and OZ/Z comparisons). Mean day 0 to day 2 viral load decrease was 2.14, 2.49, and 1.68 log10 cgeq/µl (p = 0.060, p = 0.016 for OZ/O and OZ/Z). Median time to alleviation of symptoms was 4.0, 3.0, and 4.0 days (+1.0, 95% CI 0.0–4.0, p = 0.018; +0.0, 95% CI −3.0 to 3.0, p = 0.960 for OZ/O and OZ/Z). Four severe adverse events were observed. Nausea and/or vomiting tended to be more frequent in the combination arm (OZ, n = 13; O, n = 4; and Z, n = 5 patients, respectively). Conclusions In adults with seasonal influenza A mainly H3N2 virus infection, the oseltamivir-zanamivir combination appeared less effective than oseltamivir monotherapy, and not significantly more effective than zanamivir monotherapy. Despite the theoretical potential for the reduction of the emergence of antiviral resistance, the lower effectiveness of this combination calls for caution in its use in clinical practice. Trial registration www.ClinicalTrials.gov NCT00799760 Please see later in the article for the Editors' Summary" @default.
• W2092142218 created "2016-06-24" @default.
• W2092142218 creator A5011349514 @default.
• W2092142218 creator A5015993425 @default.
• W2092142218 creator A5021625917 @default.
• W2092142218 creator A5032223222 @default.
• W2092142218 creator A5033790997 @default.
• W2092142218 creator A5035494566 @default.
• W2092142218 creator A5041062231 @default.
• W2092142218 creator A5043361043 @default.
• W2092142218 creator A5050236796 @default.
• W2092142218 creator A5052636813 @default.
• W2092142218 creator A5055942371 @default.
• W2092142218 creator A5062679312 @default.
• W2092142218 creator A5064690675 @default.
• W2092142218 date "2010-11-02" @default.
• W2092142218 modified "2023-10-03" @default.
• W2092142218 title "Efficacy of Oseltamivir-Zanamivir Combination Compared to Each Monotherapy for Seasonal Influenza: A Randomized Placebo-Controlled Trial" @default.
• W2092142218 cites W1700704048 @default.
• W2092142218 cites W1988044361 @default.
• W2092142218 cites W2004554957 @default.
• W2092142218 cites W2020585508 @default.
• W2092142218 cites W2031849137 @default.
• W2092142218 cites W2043580251 @default.
• W2092142218 cites W2072658090 @default.
• W2092142218 cites W2080927210 @default.
• W2092142218 cites W2093867498 @default.
• W2092142218 cites W2124505709 @default.
• W2092142218 cites W2128060816 @default.
• W2092142218 cites W2129728733 @default.
• W2092142218 cites W2134121879 @default.
• W2092142218 cites W2150047295 @default.
• W2092142218 cites W2150238349 @default.
• W2092142218 cites W2163949383 @default.
• W2092142218 cites W2312463092 @default.
• W2092142218 cites W2334261876 @default.
• W2092142218 cites W4210868240 @default.
• W2092142218 cites W94004259 @default.
• W2092142218 doi "https://doi.org/10.1371/journal.pmed.1000362" @default.
• W2092142218 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3014601" @default.
• W2092142218 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21072246" @default.
• W2092142218 hasPublicationYear "2010" @default.
• W2092142218 type Work @default.
• W2092142218 sameAs 2092142218 @default.
• W2092142218 citedByCount "108" @default.
• W2092142218 countsByYear W20921422182012 @default.
• W2092142218 countsByYear W20921422182013 @default.
• W2092142218 countsByYear W20921422182014 @default.
• W2092142218 countsByYear W20921422182015 @default.
• W2092142218 countsByYear W20921422182016 @default.
• W2092142218 countsByYear W20921422182017 @default.
• W2092142218 countsByYear W20921422182018 @default.
• W2092142218 countsByYear W20921422182019 @default.
• W2092142218 countsByYear W20921422182020 @default.
• W2092142218 countsByYear W20921422182021 @default.
• W2092142218 countsByYear W20921422182022 @default.
• W2092142218 countsByYear W20921422182023 @default.
• W2092142218 crossrefType "journal-article" @default.
• W2092142218 hasAuthorship W2092142218A5011349514 @default.
• W2092142218 hasAuthorship W2092142218A5015993425 @default.
• W2092142218 hasAuthorship W2092142218A5021625917 @default.
• W2092142218 hasAuthorship W2092142218A5032223222 @default.
• W2092142218 hasAuthorship W2092142218A5033790997 @default.
• W2092142218 hasAuthorship W2092142218A5035494566 @default.
• W2092142218 hasAuthorship W2092142218A5041062231 @default.
• W2092142218 hasAuthorship W2092142218A5043361043 @default.
• W2092142218 hasAuthorship W2092142218A5050236796 @default.
• W2092142218 hasAuthorship W2092142218A5052636813 @default.
• W2092142218 hasAuthorship W2092142218A5055942371 @default.
• W2092142218 hasAuthorship W2092142218A5062679312 @default.
• W2092142218 hasAuthorship W2092142218A5064690675 @default.
• W2092142218 hasBestOaLocation W20921422181 @default.
• W2092142218 hasConcept C126322002 @default.
• W2092142218 hasConcept C134164806 @default.
• W2092142218 hasConcept C142724271 @default.
• W2092142218 hasConcept C168563851 @default.
• W2092142218 hasConcept C203014093 @default.
• W2092142218 hasConcept C204787440 @default.
• W2092142218 hasConcept C2522874641 @default.
• W2092142218 hasConcept C27081682 @default.
• W2092142218 hasConcept C2777538117 @default.
• W2092142218 hasConcept C2779134260 @default.
• W2092142218 hasConcept C2780374985 @default.
• W2092142218 hasConcept C2781442963 @default.
• W2092142218 hasConcept C3008058167 @default.
• W2092142218 hasConcept C44249647 @default.
• W2092142218 hasConcept C524204448 @default.
• W2092142218 hasConcept C71924100 @default.
• W2092142218 hasConceptScore W2092142218C126322002 @default.
• W2092142218 hasConceptScore W2092142218C134164806 @default.
• W2092142218 hasConceptScore W2092142218C142724271 @default.
• W2092142218 hasConceptScore W2092142218C168563851 @default.
• W2092142218 hasConceptScore W2092142218C203014093 @default.
• W2092142218 hasConceptScore W2092142218C204787440 @default.
• W2092142218 hasConceptScore W2092142218C2522874641 @default.
• W2092142218 hasConceptScore W2092142218C27081682 @default.
• W2092142218 hasConceptScore W2092142218C2777538117 @default.
• W2092142218 hasConceptScore W2092142218C2779134260 @default.

• next